Genmab A/S

GMAB

DK0010272202

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen Other stock markets 16:20:00 05/07/2024 BST			5-day change	1st Jan Change
1,755 ^DKK	+0.98%		+0.57%	-18.56%

06-28	Would you like some more inflation?
06-28	Genmab, AbbVie's Lymphoma Therapy Recommended for Approval in EU	MT

Genmab A/S Reports Sales Results for the Year 2018

January 08, 2019 at 05:34 pm

Genmab A/S reported sales results for the year 2018. The company reported sales of DARZALEX reached USD 2 billion in the calendar year of 2018.

Latest news about Genmab A/S

Would you like some more inflation?	06-28
Genmab, AbbVie's Lymphoma Therapy Recommended for Approval in EU	06-28	MT
AbbVie, Genmab Receive Positive European Opinion on Marketing Authorization for Possible Lymphoma Treatment	06-28	MT
Genmab A/S Announces Epcoritamab Receives Positive CHMP Opinion for Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma	06-28	CI
AbbVie Receives Positive CHMP Opinion for Epcoritamab for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma	06-28	CI
Genmab Closes DKK3.5 Billion Share Buyback Early	06-28	MT
BTIG Adjusts Price Target on Genmab to $47 From $46, Maintains Buy Rating	06-27	MT
Genmab Gets FDA Approval for Follicular Lymphoma Treatment	06-27	MT
Genmab Wins US Approval for Follicular Lymphoma Treatment	06-27	MT
Genmab A/S Announces That the U.S. Food and Drug Administration Approved Epkinly® (Epcoritamab-Bysp) for the Treatment of Adults with Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic EPKINLY	06-27	CI
U.S. Food and Drug Administration Grants Second Approval for AbbVie's EPKINLY (epcoritamab-bysp) to Treat Patients with Relapsed or Refractory Follicular Lymphoma	06-27	CI
AbbVie Gets New FDA Accelerated Approval for Epkinly	06-26	DJ
Transcript : Genmab A/S Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 09:20 AM	06-10
Truist Securities Raises Price Target on Genmab to $53 From $50, Maintains Buy Rating	06-04	MT
Genmab's Tisotumab Shows 'Encouraging' Antitumor Activity in Phase 2 Head, Neck Cancer Study	06-03	MT
Transcript : Genmab A/S - Special Call	06-03
Genmab A/S Announces Data from the Phase 2 Innovatv 207 Trial, Investigating Tisotumab Vedotin	06-03	CI
Genmab A S and BioNTech SE Announces Initial Data from the Ongoing Phase 2 Trial	06-03	CI
Genmab Announces Initial Data from Phase 2 Cancer Treatment Trial	06-03	MT
Genmab A/S Announces New Efficacy and Safety Data from Two Ongoing Phase 1/2 Clinical Trials Evaluating Epcoritamab, A T-Cell Engaging Bispecific Antibody Administered Subcutaneously, in Adult Patients with Certain Types of Follicular Lymphoma	06-02	CI
Genmab A/S and Biontech SE Announce Initial Data from the Phase 2 Gct1046-04 Trial (NCT05117242) Evaluating Acasunlimab	06-01	CI
Genmab A/S Reaffirms Financial Guidance for 2024	05-21	CI
Genmab A/S completed the acquisition of ProfoundBio, Inc.	05-20	CI
Genmab CEO Says Western Firms Should Tap Into China's 'Impressive Innovation'	05-15	MT
Bolt Biotherapeutics Stops Development of Trastuzumab Imbotolimod, Cuts Workforce by 50%	05-15	MT

Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (83.2%); - income from research and development (12.4%); - other (4.4%): primarily income from partnership agreement. At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase. Denmark accounts for all net sales.

Sector

Biotechnology & Medical Research

Calendar

01/08/2024 - Q2 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

GENMAB : A good start to 2024; guidance unchanged

May 03, 2024 at 06:08 pm

More Strategies

Ratings for Genmab A/S

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1,755 DKK

Average target price

2,464 DKK

Spread / Average Target

+40.40%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
GENMAB A/S	-18.56%	16.17B
VERTEX PHARMACEUTICALS INCORPORATED	+16.61%	122B
REGENERON PHARMACEUTICALS, INC.	+17.75%	112B
ARGENX SE	+17.23%	25.91B
BIONTECH SE	-24.11%	19.33B
BEIGENE, LTD.	-18.47%	15.6B
WUXI APPTEC CO., LTD.	-47.75%	14.65B
SAREPTA THERAPEUTICS, INC.	+57.35%	14.34B
NEUROCRINE BIOSCIENCES, INC.	+5.62%	14B
INSMED INCORPORATED	+125.88%	11.29B

Bio Therapeutic Drugs

Genmab A/S

Equities

GMAB

DK0010272202

Biotechnology & Medical Research

Genmab A/S Reports Sales Results for the Year 2018

Latest news about Genmab A/S

Chart Genmab A/S

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Genmab A/S

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs